Beam Therapeutics BEAM
- Market cap
- $2.7B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 17.1×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $146.6M
- +163% on a year ago
- Net margin
- −54.7%
- Free cash flow yield
- −14.0%
Beam Therapeutics trades at 17.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $146.6M over the last twelve months, up 163% on a year earlier with a −55% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $316.2M+1478% | $7.4M−69% | $11.8M−42% | $14.3M−17% | $30.1M−91% | $7.5M+1% | $8.5M−28% | $9.7M−32% | $114.1M+280% | $31.7M+325% | $490K−94% | $307K−97% | |
| R&D | $140.1M+62% | $84.8M−15% | $87M−11% | $94.3M−6% | $101.4M−28% | $98.8M+17% | $101.8M+17% | $109.8M+17% | $99.3M−2% | $104.5M+6% | $95.1M−7% | $110.1M+0% |
| SG&A | $43.3M+91% | $26.7M+14% | $29.6M+20% | $26.5M+4% | $28.7M−34% | $27.9M+5% | $26.9M−9% | $26.7M+1% | $32.3M+13% | $34.4M+23% | $31.9M+19% | $31.5M+18% |
| $132.9M | −$104.1M+5% | −$104.9M+3% | −$106.5M−2% | −$100M | −$119.3M+15% | −$120.2M+15% | −$126.8M+19% | −$17.4M−83% | −$107.2M−10% | −$126.6M+5% | −$141.3M+11% | |
| Pre-tax income | $144.2M | n/a | −$91M+10% | −$96.7M+1% | −$90.4M | n/a | −$102.3M+12% | −$112.7M+17% | $244.3M | n/a | n/a | n/a |
| $1.4M+37% | n/a | $39K | $0 | $0 | n/a | n/a | $0 | $0 | n/a | n/a | n/a | |
| Net income | $142.8M | −$98.7M+2% | −$91.1M+10% | −$96.7M+1% | −$90.4M | −$108.3M+10% | −$102.1M+12% | −$112.6M+17% | $244.3M | −$94.3M−13% | −$122.7M+20% | −$134.4M+19% |
| $1.77 | −$1.21−9% | −$1.11+3% | −$1.17−4% | −$1.09 | −$1.23+2% | −$1.00−10% | −$1.10−6% | $2.37 | −$0.91−26% | −$1.18+18% | −$1.28+16% | |
| 80.9M+14% | 81.7M+13% | 82.3M+8% | 82.4M+4% | 82.8M+2% | 88M+8% | 102M+24% | 102.6M+25% | 102.9M+24% | 103.3M+17% | 104.3M+2% | 104.7M+2% |
Revenue: Q1 FY19: 6 months less the 3 months printed beside them.
EPS, diluted: 7 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY19 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Beam Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BEAMBeam Therapeutics | $2.7B | n/m | n/a | n/m | 17.1× | +163% | −54.7% |
| ADMAAdma Biologics | $2.5B | 15.8× | 21.3× | n/m | 4.8× | +8% | 33.0% |
| VCELVericel | $2.1B | 88.1× | 157× | n/m | 6.8× | +23% | 7.9% |
| MGTXMeiraGTx | $895.1M | 13.1× | 15.4× | n/m | 2.3× | n/m | 19.9% |
| KRYSKrystal Biotech | $8.8B | 37.1× | 42.5× | n/m | 19.9× | +23% | 54.8% |
| RGENRepligen | $9.8B | 237× | 123× | n/m | 12.4× | +16% | 5.3% |
| TECHBIO-TECHNE | $11.4B | 63.2× | 62.0× | n/m | 9.4× | −0% | 15.0% |
| HALOHalozyme Therapeutics | $14.6B | 38.5× | 21.3× | n/m | 8.8× | +41% | 24.9% |
| NBIXNeurocrine Biosciences | $14.8B | 21.3× | 42.6× | n/m | 4.4× | +34% | 20.9% |
| EXELExelixis | $17.4B | 22.1× | 22.7× | n/m | 7.1× | +9% | 35.3% |
| ALNYAlnylam Pharmaceuticals | $21.2B | 26.7× | 68.2× | 18.9× | 4.4× | +95% | 16.8% |
| Peer median | $10.6B | 31.9× | 42.6× | 18.9× | 7.0× | +23% | 20.4% |
Investors who own it
Investors we follow who held Beam Therapeutics at the end of Jun 30, 2026, from their 13F filings.
- Cathie WoodARK Investment Management2.3% of portfoliotrimmed
- Stanley DruckenmillerDuquesne Family Office0.1% of portfolionew
- Baillie GiffordBaillie Gifford0.0% of portfoliotrimmed
More on Beam Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #7of 340Healthcare stocks with the fastest revenue growth
- #4of 36Biotech stocks with the fastest revenue growth
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .